The Monash
University Institute of Pharmaceutical Sciences (MIPS) announced
positive results from a first-in-human study of a new, inhaled form of a
medicine that could significantly reduce maternal deaths around the
world. The results open the possibility of a streamlined pathway to
registration, meaning that the medicine could be accessible to mothers
much sooner than would otherwise be possible.
Every year, over 300,000 women in low
and low-middle income countries die during pregnancy and childbirth.
Postpartum haemorrhage (PPH) is the single largest cause of these
deaths.
PPH can be prevented by administering a drug called oxytocin, which is recommended by the World Health Organisation and
is widely used in wealthy countries. However, as an injection, oxytocin
requires refrigeration and a skilled medical professional to administer
it safely. In low and low-middle income countries, one or both of these
requirements may not be available.
To address this unmet need, researchers
at MIPS, in collaboration with GlaxoSmithKline in London, who sponsored
the study, have been developing an inhalable, dry-powder form of
oxytocin.
The Royal College of Obstetricians and
Gynaecologists World Congress in Cape Town, South Africa, the results of
the first in-human trial of the new formulation were announced.
The study demonstrated, in a small
cohort of non-pregnant female volunteers, that the effects that inhaled
oxytocin has on the body are not meaningfully different from its
injected counterpart. This gives confidence that the inhaled form of
oxytocin will deliver similar effects in prevention of PPH when given to
mothers immediately after giving birth.
The results present the possibility that
the new medicine will be able to take advantage of a streamlined
pathway to registration, meaning that it could reach the mothers who
need it much sooner.
Associate Professor Michelle McIntosh,
Project Leader at MIPS, said that this first in-human data offers hope
to the many women in resource-constrained settings who do not currently
have access to this essential medicine.
“These results show that oxytocin can be
delivered similarly via inhalation or injection and therefore we are
less likely to be required to conduct the extensive and costly trials
needed for an entirely new drug. Instead, we should be able to move
forward with trials on a much smaller scale, featuring patients
numbering in the hundreds rather than tens of thousands, potentially
making the medicine available much sooner,” Associate Professor McIntosh
said.
This positive data has supported the
initiation of clinical studies evaluating inhaled oxytocin when given to
women immediately after birth, the time at which oxytocin is routinely
administered for prevention of PPH.